OCEVA Injection 1's

Introduction About OCEVA INJECTION

Oceva 10 mg/mL Injection contains r
administered by an ophthalmologist into the eye. It is used for retinal
conditions in which abnormal blood-vessel growth or leakage causes vision
impairment, including wet age-related macular degeneration, diabetic macular
oedema, macular oedema following retinal vein occlusion, proliferative diabetic
retinopathy, and certain forms of choroidal neovascularisation. It may also be
used in premature infants with retinopathy of prematurity when specifically
indicated by a specialist.

Oceva is intended for patients whose retinal condition has been confirmed by an
eye specialist and who require anti-VEGF therapy. The injection is not
self-administered; it is given by a trained ophthalmologist under sterile
conditions after appropriate eye preparation. The injection schedule depends on
the retinal condition, response to therapy, and the specialist's treatment plan.
Patients should attend scheduled eye examinations and monitoring visits, as
repeated injections may be required.

Before administration, inform the ophthalmologist about any active eye
infection, inflammation inside the eye, previous eye procedures, stroke or
cardiovascular history, pregnancy, breastfeeding, allergies, and all medicines
or supplements being used. The injection should not be administered when there
is an active infection in or around the eye or severe intraocular inflammation.
Temporary visual disturbances can occur after administration, so patients should
avoid driving or operating machinery until vision has returned to normal.

During pregnancy, Oceva should be used only when the ophthalmologist considers
that the expected benefit justifies potential fetal risk; women who could become
pregnant should discuss appropriate contrace
professional. Breastfeeding also requires specialist advice because human milk
exposure and effects on the infant are not fully established. Commonly reported
effects include eye pain or irritation, conjunctival bleeding, eye inflammation,
increased eye pressure, floaters, dry eye, redness, itching, and temporary
blurred vision. Persistent or worsening eye pain, redness, reduced vision,
increased sensitivity to light, or other significant visual changes require
prompt ophthalmic assessment.

Uses Of OCEVA INJECTION

• Diabetic eye disease
• Wet age-related macular degeneration
• Macular edema due to retinal vein occlusion
• Macular edema due to pathological myopia

Benefits of OCEVA INJECTION

Supports Retinal Health and Vision

• Helps reduce abnormal blood-vessel growth in the retina.
• Reduces leakage of fluid from abnormal retinal blood vessels.
• Helps reduce retinal swelling associated with VEGF activity.
• May help stabilize or improve visual acuity in appropriately selected patients.

Supports Management of Diabetic Retinal Conditions

• Helps reduce retinal fluid leakage associated with diabetic macular oedema.
• May improve visual function in patients with diabetic retinal disease when prescribed by an ophthalmologist.

Supports Management of Wet AMD and Retinal Vein Occlusion

• Helps limit abnormal blood-vessel activity associated with wet AMD.
• Helps reduce macular swelling associated with retinal vein occlusion.
• Supports preservation of central vision in suitable patients.

How OCEVA INJECTION Works

VEGF-A Blockade

• R
• It binds VEGF-A with high affinity.
• This prevents VEGF-A from binding to its receptors, VEGFR-1 and VEGFR-2, on vascular endothelial cells.

Reduced Abnormal Blood-Vessel Activity

• VEGF-A promotes abnormal blood-vessel growth and increases vascular permeability.
• By blocking VEGF-A, r
• Reduced leakage helps decrease fluid accumulation and swelling in the retina.

Overall Retinal Effect

• Less abnormal vascular leakage can reduce retinal oedema.
• Controlling abnormal vascular activity helps preserve retinal structure and visual function in the conditions for which r

How to use OCEVA INJECTION

• Oceva must be administered by a qualified ophthalmologist experienced in intravitreal injections; it must not be self-administered.
• Implant: It will be inserted into the white part of your eye with a needle by a doctor in a medical office or clinic.
• The injection is administered directly into the vitreous cavity of the affected eye under sterile conditions.
• Before administration, the eye is cleaned and a local anaesthetic is generally used to reduce discomfort.
• The exact dose and injection schedule depend on the retinal condition and the ophthalmologist's treatment plan.
• For adult r
• Regular retinal examinations and visual assessments are important because repeat injections may be required.
• Patients should attend every scheduled ophthalmology appointment, even when vision appears stable.
• Temporary blurred vision may occur after injection; do not drive or operate machinery until vision has returned to normal.

What if I forgot to take OCEVA INJECTION

If you miss a dose of Oceva 10mg/ml Injection, please consult your doctor.

Overdose

• Cases of accidental overdose have been reported from the clinical studies in wet AMD and post-marketing data.
• Adverse reactions associated with these reported cases were intraocular pressure increased, transient blindness, reduced visual acuity, corneal oedema, corneal pain, and eye pain.
• If an overdose occurs, intraocular pressure should be monitored and treated, if deemed necessary by the attending physician.

Side Effects Of OCEVA INJECTION

Common side effects of Oceva

• Conjunctival hemorrhage
• Eye pain
• Increased intraocular pressure
• Foreign body sensation in eyes
• Blurred vision
• Nausea
• Dry eye
• Eye itching
• Cataract
• Vitreous floaters
• Vitreous detachment
• Intraocular inflammation
• Eye irritation
• Increased lacrimation
• Eyelid inflammation
• Ocular hyperemia
• Retinal disorder
• Maculopathy
• Eye discomfort
• Posterior capsule opacification
• Injection site hemorrhage
• Nasopharyngitis (inflammation of the throat and nasal passages)
• Anemia (low number of red blood cells)
• Joint pain
• Renal failure
• Peripheral neuropathy (tingling and numbness of feet and hand)
• Gastro-esophageal reflux disease
• Hypercholesterolemia (high cholesterol)
• Bronchitis (inflammation of the airways)

Warning & Precautions

!### Pregnancy

Consult your doctorR
benefit clearly outweighs the potential risk to the fetus. There are limited
clinical data on exposure during pregnancy.

Women who could become pregnant should use effective contrace
therapy and for at least 3 months after the last injection according to the
product information.  Women planning pregnancy should discuss the timing of
treatment with their ophthalmologist.

!### Breastfeeding

ContraindicatedBreastfeeding is not recommended during r
information suggests that small amounts may pass into human milk, while the
effect on a breastfed infant is not established

!### Driving and Using Machines

Use with CautionTemporary blurred vision or other visual disturbances can occur after the
intravitreal injection. Do not drive, cycle, or operate machinery until vision
has returned to normal.

Arrange transportation home after the injection when appropriate, particularly
if both eyes are being managed or vision is significantly affected.

!### Alcohol

Consult your doctorNo specific clinically significant alcohol interaction with intravitreal
r

!### Kidney

Consult your doctorDose adjustment is generally not required in renal impairment.

!### Liver

Consult your doctorR
but no special dose adjustment is generally considered necessary based on
available product information.

!### Allergy

ContraindicatedDo not receive Oceva 10mg/ml Injection if you are allergic to any of its
components, if you have an infection in or around the eye, severe intraocular
inflammation (pain or redness in the eye)

!### Heart Disease

Monitoring requiredBecause VEGF inhibition may potentially affect vascular function, patients with
a history of stroke, transient ischemic attack, myocardial infarction, or other
serious cardiovascular disease should inform their ophthalmologist before
therapy.

Patients should be monitored according to their underlying cardiovascular risk
and the specific retinal condition. Seek urgent medical attention for symptoms
suggestive of a stroke or other major cardiovascular event, such as sudden
weakness, difficulty speaking, severe chest discomfort, or sudden shortness of
breath.

!### Use In Pediatrics

Consult your doctorUse in children and adolescents depends on the specific indication. For most
adult retinal indications, safety and efficacy in patients below 18 years have
not been established.

!### Use In Geriatrics

Consult your doctorNo specific dose adjustment is generally required in elderly patients. Older
adults may have multiple eye and cardiovascular conditions, so the
ophthalmologist should review their complete medical history and medicines.

Patients older than 75 years may have more limited clinical experience for some
indications, so individualized monitoring is appropriate.

Drug - Drug interaction

Other Anti-VEGF Medicines

• Concurrent use of other anti-VEGF medicines, whether ocular or systemic, is generally not recommended unless specifically directed by a retinal specialist.
• Combining anti-VEGF therapies may increase overall exposure to VEGF inhibition and has limited clinical evidence.

Verteporfin Photodynamic Therapy

• R
• This combination should be planned and monitored by an ophthalmologist because intraocular inflammation has been reported when the therapies are used together.

Laser Photocoagulation

• R
• The timing and suitability of combined therapy should be determined by the treating ophthalmologist.

Thiazolidinediones

• Clinical studies in diabetic macular oedema found that concomitant use of thiazolidinediones did not significantly alter visual-acuity or retinal-thickness outcomes with r
• Examples include pioglitazone and rosiglitazone.

Medicines Affecting Bleeding

Oceva does not have a well-established direct interaction with blood thinners,
but patients taking medicines that affect bleeding should inform their
ophthalmologist because intravitreal injection itself can cause ocular bleeding.

Examples include:

• Warfarin
• Apixaban
• Rivaroxaban
• Aspirin
• Clopidogrel
• Ticagrelor

Do not stop these medicines before an eye injection unless the prescribing
doctor specifically advises it.

Synopsis

Drug	R
Pharmacological Category	vascular endothelial growth factor blocker
Therapeutic Indication	Eye conditions
Dosage Forms	Ophthalmic injection

More Information

1. The 10 mg/mL Strength Is a Concentration, Not the Usual Adult Injected Dose

Oceva is supplied at a concentration of 10 mg/mL, but the amount injected into
the eye is much smaller than 1 mL. For the common adult r
mg, the corresponding volume is 0.05 mL. The exact dose depends on the
indication and specialist's prescri

This distinction is particularly useful on e-pharmacy product pages because
patients may otherwise assume that the entire 1 mL volume is injected.

2. Vision Can Fluctuate After an Injection

Temporary blurred vision or visual disturbance can occur following intravitreal
administration. Patients should arrange appropriate transport when necessary and
avoid driving until vision has returned to normal.

3. Eye Pressure May Need Monitoring

Intravitreal r
(IOP) immediately after injection. Ophthalmologists may therefore check eye
pressure before and/or after administration, particularly in patients with
glaucoma or other risk factors.

4. Injection Technique Is a Major Safety Factor

Because the medicine is injected directly into the eye, sterile technique is
essential. Serious complications such as endophthalmitis and retinal detachment
are recognized risks of intravitreal injections. Patients should promptly report
increasing eye pain, redness, worsening vision, new floaters, or increased
sensitivity to light.

5. Cardiovascular History Matters

VEGF inhibition may be associated with a potential risk of arterial
thromboembolic events, including stroke and myocardial infarction. Patients with
a history of stroke, transient ischemic attack, or recent cardiovascular events
should ensure that their ophthalmologist has this information before treatment.

6. Treatment Usually Requires Ongoing Eye Monitoring

R
conditions. The ophthalmologist may repeat treatment based on visual acuity,
retinal findings, o
interval between injections is individualized according to the indication and
response.

FAQs About OCEVA INJECTION

Q: What is Oceva 10 mg/mL Injection used for?

A: Oceva 10 mg/mL Injection contains r
ophthalmologist for certain retinal conditions involving abnormal blood-vessel
growth or leakage, such as wet age-related macular degeneration, diabetic
macular oedema, and macular oedema associated with retinal vein occlusion.

Q: How is Oceva Injection administered?

A: Oceva is given as an intravitreal injection, me
into the vitreous cavity of the eye by a qualified ophthalmologist under sterile
conditions. It should never be self-administered.

Q: How often is Oceva Injection given?

A: The injection schedule depends on the retinal condition, visual response,
retinal findings, and the ophthalmologist's treatment plan. Some patients may
require repeated injections at regular intervals.

Q: Does Oceva Injection improve vision?

A: By reducing abnormal blood-vessel leakage and retinal swelling, r
may help stabilize or improve vision in appropriately selected patients. The
response varies according to the underlying eye condition.

Q: Can I drive after receiving Oceva Injection?

A: Temporary blurred vision or other visual disturbances can occur after the
injection. Do not drive or operate machinery until your vision has returned to
normal.

Q: What should I tell my ophthalmologist before receiving Oceva?

A: Inform the ophthalmologist about any eye infection or inflammation, glaucoma,
previous eye procedures, history of stroke or heart problems, pregnancy or
breastfeeding, allergies, and all medicines or supplements you are taking.

Q: Can Oceva be used during pregnancy?

A: Oceva should generally be avoided during pregnancy unless the expected
benefit clearly outweighs the potential risk. Women who could become pregnant
should discuss effective contrace
ophthalmologist.

Q: Can Oceva be used while breastfeeding?

A: Breastfeeding is generally not recommended during r
the effects of exposure on a breastfed infant are not sufficiently established.
Discuss the appropriate o

Q: What symptoms require prompt medical attention after an Oceva injection?

A: Seek urgent ophthalmic care for increasing eye pain, severe redness, sudden
reduction in vision, marked sensitivity to light, new or worsening floaters, or
other significant changes in vision, as these may indicate a serious eye
complication.

Q: How should Oceva 10 mg/mL Injection be stored?

A: Store the injection under refrigerated conditions, generally at 2°C to 8°C,
protect it from light, and do not freeze it. Follow the manufacturer's storage
instructions until the medicine is administered.